-
Great changes have taken place in the practice system of Chinese physicians!
Time of Update: 2021-09-29
The "Interim Measures" stipulate that after a doctor has been registered and obtained a "Physician's Practicing Certificate", he may engage in corresponding medical treatment, prevention, and health care activities in accordance with the registered practice location, practice category, and practice scope .
-
No entry: Neurology clinic refuses to use Aduhelm, a new drug for Alzheimer's disease
Time of Update: 2021-09-29
According to a note on its website, considering the high price of Aduhelm-the average annual treatment cost per patient is $56,000-and the ambiguous clinical benefits, doctors at the Neurology Center have agreed to refuse to use it until the dispute is clarified.
-
INOVIO authorized to conduct vaccine candidate trials in Mexico
Time of Update: 2021-09-29
The company recently received regulatory authorization to conduct trials in Brazil and the Philippines INOVIO and partner Ai Di Weixin are collaborating in a global phase 3 trial in regions with insuf
-
CSCO2021 Professor Li Jin: New Hope for HER2 Positive Solid Tumors New ADC Drug MRG002 Phase I Study Announced
Time of Update: 2021-09-29
On September 25-29, 2021, the 24th National Conference on Clinical Oncology and the 2021 CSCO Academic Annual Meeting will be held as scheduled to promote the continuous development of China's oncolog
-
Under the collection!
Time of Update: 2021-09-29
Who knows that starting from 2020, the state has implemented centralized bidding for products that are currently in large quantities in hospitals and commonly used by the people, and the policy of mass procurement has greatly reduced the number of drugs.
-
As the domestic ADC drug market continues to develop, competition is increasing
Time of Update: 2021-09-29
The announcement showed that SHR-A1904 for injection is an antibody-drug conjugate targeting tumor-specific antigens.
In recent years, with the continuous maturity of ADC drug research and development technology, this market has gradually become hot, and it is attracting more and more companies to enter this field .
-
With the vigorous development of my country's pharmaceutical industry, the importance of pharmaceutical packaging equipment will increase day by day
Time of Update: 2021-09-29
The analysis believes that with the development of the pharmaceutical packaging market and the continuous investment of pharmaceutical companies, the intelligent and green pharmaceutical packaging equipment in the future may become the main trend of the development of the industry .
-
With the help of policies, the children's drug market ushered in a period of development!
Time of Update: 2021-09-29
On the whole, China's children's medicine market is ushering in new development opportunities .
-
Obtained FDA Fast Track Qualification!
Time of Update: 2021-09-29
Prior to this, APG-115 has obtained five orphan drug qualifications (ODD) granted by the FDA, one of which is indicated for stage IIB-IV melanoma .
About Yasheng PharmaceuticalAbout Yasheng PharmaceuticalAscent Pharmaceuticals is an original innovative drug research and development company based in China and facing the world in the clinical development stage.
-
Changes in drug-related insurance in the past three years: low prices, selling points and perceptions
Time of Update: 2021-09-29
Data source: Latitude Health databaseFrom the perspective of the top ten medicines, mainly high-priced drugs newly included in the medical insurance catalogue, which can effectively control risks.
-
Peking University Medicine's antipyretic, analgesic and anti-inflammatory drug Celecoxib Capsules obtained "Drug Registration Certificate"
Time of Update: 2021-09-29
On September 23, Peking University Pharmaceutical issued an announcement stating that the company's product Celecoxib capsules had recently received the "Drug Registration Certificate" approved and issued by the State Drug Administration .
-
Hyundai Pharmaceutical Holding Subsidiary Receives Marketing License for Relycoxib Tablets
Time of Update: 2021-09-29
On September 23, Hyundai Pharmaceutical issued an announcement stating that its controlling subsidiary Sinopharm Zhijun received the "Drug Supplementary Application Approval Notice" approved and issued by the National Medical Products Administration, and agreed to rely on the marketing license of coxib tablets (30mg, 60mg).
-
19 provinces opened the curtain on the centralized procurement of Chinese patent medicines, and how would it affect?
Time of Update: 2021-09-29
On September 25, the Hubei Province Pharmaceutical Price and Bidding Purchasing Management Service Network issued the "Announcement of the Centralized Procurement of Proprietary Chinese Patent Medicines (No.
-
WuXi Giant Nuo announces the 1-year research data of Regi-Olenza injection at the 24th Chinese Society of Clinical Oncology (CSCO) Annual Meeting
Time of Update: 2021-09-29
Shanghai, September 26, 2021/PRNewswire/ - WuXi Juno (HKEx code: 2126), an innovative biotechnology company focused on the development, production and commercialization of cellular immunotherapy products The 24th Chinese Society of Clinical Oncology (CSCO) announced the 1-year follow-up data for the treatment of relapsed/refractory large B-cell lymphoma (r/r LBCL) (RELIANCE study) with Ruiji Orensai injection .
-
Eli Lilly’s application for new indications for IL-17A inhibitors is accepted by CDE
Time of Update: 2021-09-29
At present, the drug has been approved by the FDA to treat a variety of diseases, including moderate to severe plaque psoriasis, active psoriatic arthritis (PsA) in adult patients, ankylosing spondylitis, and active inflammation with objective symptoms non-radiological for axial spondyloarthritis (nr-axSpA) patients, and so on .
-
High-end pharmaceutical equipment has become a new driving force for the growth of pharmaceutical machine companies!
Time of Update: 2021-09-29
Among them, it is worth mentioning that, in the context of the continuous expansion of the domestic pharmaceutical equipment industry and the relatively complete product range, in order to meet the rising demand of pharmaceutical companies and increase the breakthrough of their own performance, many pharmaceutical equipment companies have Begin to accelerate its march into the high-end market .
-
19 provinces announced the time for the fifth batch of national procurement bids!
Time of Update: 2021-09-29
The summary is as follows:Shanxi ProvinceShanxi ProvinceOn September 26, the Shanxi Provincial Medical Insurance Bureau, together with the Shanxi Provincial Health Commission and the Food and Drug Administration, issued the "Notice on the Full Implementation of the Fifth Batch of National Organized Drug Centralized Procurement and the Selection Results of the "Eight Provinces and Two Districts" Inter-Provincial Alliance Drug Centralized Procurement" (Jinyibaofa [2021] No.
-
Olin Biosorbent Tetanus Vaccine Obtained Drug Re-registration Approval Notice
Time of Update: 2021-09-29
Upon review, the company declared that the adsorbed tetanus vaccine complied with the "Administrative Measures for Drug Registration" 》, agree to re-register .
The company obtained the first registration approval for tetanus vaccine drug in October 2016.
-
Kangfang Bio-PD-1/CTLA-4 dual antibody listing application accepted
Time of Update: 2021-09-29
Specific to the indications of cervical cancer, clinical research data shows that kaidenizumab is effective in treating patients with relapsed or metastatic cervical cancer who have failed platinum-containing chemotherapy, and has good safety .
-
National centralized procurement continues to advance, and drug price reductions will become the general trend
Time of Update: 2021-09-29
and other companies to actively cut prices in Liaoning Province According to the "Implementation Plan for Centralized Procurement of Medicines in Medical Institutions of Liaoning Province", it was agreed to adjust the online purchase price of the above-mentioned products .
